Published in Clin Lab Haematol on September 01, 1994
Cellular mechanisms of multiple myeloma bone disease. Clin Dev Immunol (2013) 0.96
The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies. Blood Cancer J (2015) 0.86
Common single nucleotide polymorphisms in immunoregulatory genes and multiple myeloma risk among women in Connecticut. Am J Hematol (2010) 0.81
Spontaneous remission in acute myeloid leukaemia. Br J Haematol (1994) 2.30
The reappearance of 10 differentiation antigens on peripheral blood lymphocytes after allogeneic bone marrow transplantation. Bone Marrow Transplant (1991) 2.12
Serum immunoreactive interleukin-6 and C-reactive protein levels in patients with multiple myeloma at diagnosis. Br J Haematol (1994) 1.16
Febrile infection changes the expression of IgG Fc receptors and complement receptors in human neutrophils in vivo. Clin Exp Immunol (1997) 1.06
Feasibility of prolonged use of interferon-alpha in metastatic kidney carcinoma: a phase II study. Cancer (2001) 1.00
Serine hydroxymethyltransferase activity and serine incorporation in leukocytes. Cancer Res (1979) 0.96
Biochemical mechanisms in the Killmann experiment: critique of the deoxyuridine suppression test. J Clin Invest (1980) 0.89
Expression of L-myc and N-myc proto-oncogenes in human leukemias and leukemia cell lines. Blood (1991) 0.88
Effects of alpha-interferon on serum beta-2-microglobulin. Leuk Lymphoma (1996) 0.86
Recovery of natural killer cells after chemotherapy for childhood acute lymphoblastic leukemia and solid tumors. Med Pediatr Oncol (1995) 0.85
Interaction between dopamine and phospholipids. Studies of the substantia nigra in Parkinson disease patients. Arch Neurol (1975) 0.85
Recovery of blood B-lymphocytes and serum immunoglobulins after chemotherapy for childhood acute lymphoblastic leukemia. Cancer (1992) 0.85
Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Finnish Leukaemia Group. Br J Haematol (1996) 0.85
Recovery of blood lymphocytes and serum immunoglobulins after treatment of solid tumors in children. Pediatr Hematol Oncol (1994) 0.83
Guillan-Barré syndrome. Neurochemical and ultrastructural study. Eur Neurol (1971) 0.81
L-myc and N-myc in hematopoietic malignancies. Leuk Lymphoma (1993) 0.81
Factors stimulating collagen synthesis from the livers of hypercholesterolemic rats. Atherosclerosis (1976) 0.80
Type I diabetic pregnancy and subclinical human papillomavirus infection. Clin Infect Dis (1997) 0.80
Recovery of blood T-cell subsets after chemotherapy for childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol (1994) 0.80
Autologous blood cell transplantation in B-CLL: response to chemotherapy prior to mobilization predicts the stem cell yield. Bone Marrow Transplant (1997) 0.79
p53 gene mutations are rare in patients but common in patient-originating cell lines in multiple myeloma. Scand J Clin Lab Invest (1997) 0.79
Haematological laboratory findings in the elderly: influence of age and sex. Scand J Clin Lab Invest (1986) 0.79
VAD regimen in the treatment of resistant multiple myeloma: slow or fast infusion? Leuk Lymphoma (1993) 0.78
Studies on the pathogenesis of multiple sclerosis. 2',3'-Cyclic nucleotide 3-phosphohydrolase as marker of demyelination and correlation of findings with lysosomal changes. J Neurol Sci (1972) 0.78
Comparison between four and eight cycles of intensive chemotherapy in adult acute myeloid leukemia: a randomized trial of the Finnish Leukemia Group. Leukemia (1998) 0.78
Oxygen-induced changes in pulmonary phospholipids in the rat. J Appl Physiol (1975) 0.77
Intensive chemotherapy of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS with idarubicin and cytarabine. Leuk Res (1997) 0.77
Trimethoprim prophylaxis of acute exacerbations in chronic obstructive pulmonary diseases. Acta Med Scand (1987) 0.77
Human recombinant GM-CSF selectively primes receptor mediated respiratory burst of neutrophils in vitro. Immunol Lett (1993) 0.77
Daily measurements of blood CD34+ cells after stem cell mobilization predict stem cell yield and posttransplant hematopoietic recovery. J Hematother (1997) 0.77
Serum oncostatin M in multiple myeloma: association with prognostic factors. Br J Haematol (1997) 0.77
Fractionation of plasma lipoproteins by density gradient centrifugation in swing-out rotors. Scand J Clin Lab Invest (1974) 0.77
Peripheral blood B lymphocytes in multiple myeloma. Acta Haematol (1994) 0.77
Serum oncostatin M in multiple myeloma: impact on disease severity and prognosis. Eur J Haematol (2000) 0.75
[Hemoglobin Helsinki discovered in connection with the estimation of glycosylated hemoglobin A1]. Duodecim (1983) 0.75
Alpha interferon raises serum beta-2-microglobulin in patients with multiple myeloma. Br J Haematol (1991) 0.75
Effect of hyperlipidaemic diet and clofibrate treatment on rat erythrocyte lipids. Scand J Haematol (1976) 0.75
Flow cytometric DNA analysis and clinical correlations in multiple myeloma. Am J Clin Pathol (1992) 0.75
Interferon does not prevent leukemic evolution in patients with multiple myeloma. Leukemia (1993) 0.75
[Secondary leukemias]. Duodecim (1989) 0.75
[Megaloblastic anemia]. Duodecim (1981) 0.75
High-dose chemotherapy with autologous stem cell support for the treatment of advanced ovarian cancer--initial experience in Uppsala and Turku. Acta Obstet Gynecol Scand (1997) 0.75
[Megaloblastic anemia in patients with severe congestive heart failure]. Duodecim (1990) 0.75
[Management of hairy cell leukemia with human leukocyte interferons]. Duodecim (1987) 0.75
Peripheral blood chemiluminescence as an early indicator of successful bone marrow transplantation. Transplant Proc (1987) 0.75
Plasma cell leukemia 3 months after autologous blood cell transplantation for multiple myeloma. Bone Marrow Transplant (1998) 0.75
IL-6-receptor-mediated growth inhibition by all-trans retinoic acid but not by interferon-alpha in human myeloma cells. Ann N Y Acad Sci (1995) 0.75
Long-term treatment with GM-CSF in patients with chronic lymphocytic leukemia and recurrent neutropenic infections. Leuk Lymphoma (1998) 0.75
Alpha interferon raises serum beta-2-microglobulin in patients treated for thrombocythaemia. Br J Haematol (1993) 0.75
Allogeneic bone marrow transplantation in multiple myeloma: a report of four cases. Bone Marrow Transplant (1988) 0.75
[Alpha interferon treatment of chronic myeloproliferative disease associated thrombocytosis]. Duodecim (1993) 0.75
The stabilizing effect of glucocorticoids on human endothelial cells in culture. Scand J Clin Lab Invest (1985) 0.75
[Bone marrow transplantation--a promising new treatment for myeloma]. Duodecim (1988) 0.75
[Drug-induced agranulocytosis, erythro-aplasia and aplastic anemia]. Duodecim (1986) 0.75
[Alpha-thalassemia 1 in a Finnish child]. Duodecim (1981) 0.75
[Trimethoprim does not cause folic acid deficiency]. Duodecim (1984) 0.75
[From bone marrow transplantation to blood stem cell transplantation. Experiences from the first 100 autologous stem cell transplantation in Turku]. Duodecim (1997) 0.75
Neutrophils are responsible for the reappearance of chemiluminescence after allogeneic bone marrow transplantation. Bone Marrow Transplant (1990) 0.75
Lipid composition on substantia nigra in Parkinson's disease. Acta Neurol Scand Suppl (1972) 0.75
GM-CSF raises serum levels of beta 2-microglobulin and thymidine kinase in patients with chronic lymphocytic leukaemia. Br J Haematol (1996) 0.75